1. MONITORING MEDICINE AVAILABILITY AND PRICES IN UGANDA By Denis Kibira HEPS Uganda

2. Background The Ministry of Health, in collaboration with the World Health Organization (WHO) and Health Action International Africa (HAI- Africa) represented by the Coalition for Health Promotion and Social Development (HEPS-Uganda), has since 2006 conducted medicines prices and availability monitoring in 3 sectors (public, mission, private) and four regions of the country.

3. Objective To monitor the ongoing interventions by the Ministry of Health within the Health Sector Strategic Plan to increase access to essential medicines to all Ugandans. The purpose of this activity is: To understand to what extent medicine prices contribute to problems of access to medicines in a country To Inform policymakers when selecting policy options to improve accessibility of medicines To monitor the progress of pharmaceutical policy implementation To evaluate the impact of policy or regulatory interventions Specific objectives: To Show trends in the availability of essential medicines To find out the prices (to consumers) of these medicines To assess the affordability of these medicines

4. METHODOLOGY The surveys are conducted using the standardized WHO/HAI Medicine Prices Monitoring Tool [1]. [1] Forty key (regularly prescribed and dispensed) medicines were selected for price and availability survey. The medicines, priced lowest to consumers are considered. The survey is carried out in the public, private and mission [2] facilities. [2] In the public facilities sections that provide medicines free of charge to patients are chosen and in mission facilities the survey is only carried out in facilities where medicine prices can be disaggregated (i.e. where there are set prices for medicines). The data is collected from approx. 100 randomly sampled facilities [1] www.haiweb.org/medicineprices[1] [2] According to this survey, Private sector refers to Private for Profit and Mission sector refers to Private Not for Profit[2]

5. FINDINGS Trends in availability of 40 key medicines across sectors 2006-2009 Since 2006 medicine availability across all sectors has been unpredictable with many fluctuations observed. The public sector has consistently lagged behind Availability

6. FINDINGS Availability of 40 key medicines across Urban and Rural facilities in Public sector 2006-2009 Availability was consistently higher in urban compared to rural facilities

7. FINDINGS Trend in availability of key antimalarial medicines 2006-2009 in public sector Availability of Artemether /Lumefantrine, the first line Antimalarial remained high in the public sector. Availability of the second line treatment for malaria of Quinine injection has risen by 23% since October- December 2007. However, Pyrimethamine/ Sulphadoxine used for prophylaxis has reduced by 30% since 2006.

8. FINDINGS Availability of medicines for ulcer disease, diabetes and hypertension (with highly growing morbidity) has been poorly handled in public facilities Trend in availability of 5 key medicines for chronic diseases 2006-2009 in public sector

9. FINDINGS Although availability of Oral Rehydration Salts used in management of diarrhoea has continued to be high, other Paediatric formulations continued to be stocked in less than 30 percent of public facilities. This shows that pneumonia and respiratory tract diseases common in children are not adequately catered for. Trend in availability of 4 key paediatric medicines 2006-2009 in public sector

10. MEDICINE PRICES Comparison of medicine median price ratios between and within private and mission sectors Prices charged to consumers for medicines in Private facilities were comparable across urban and rural facilities (ratio 1:1). In the Mission sector medicines in the urban facilities were 14% more expensive for consumers than in the rural facilities. A comparison between the Private sector and the Mission sector showed that medicines were 6% more costly in private urban facilities and 11% more costly in private rural facilities.

11. FINDINGS Price trends of key antimalarials- Private Sector The consumer price of Artemether/Lumefantrine (first line antimalarial) has dropped from UGX 816.5 per tablet in Oct-Dec 2006 to UGX 333.3 per tablet in July-September 2009.. Price of an ampoule of 600mg of Quinine injection (the second line antimalarial) increased from UGX 500 to UGX 700 per ampoule over the period.

12. AFFORDABILITY Affordability relates to the number of days the lowest paid government worker would have to work to pay for one treatment course of an acute condition or one month’s treatment of a chronic condition Affordability of treatment for diabetes, hypertension and pediatric acute RTI: Private Vs Mission The daily wage of the lowest paid government worker is at UShs 3,000 (1.714 US$) as per the 2006/07 Government of Uganda salary structure It would require close to 3.2 days wages for treatment in the private and 2.2 days’ wages in mission sector.

13. CONCLUSION Studies conducted indicate that availability and prices of medicines in Uganda are still a major hindrance to access to essential medicines The situation is particularly confounded for the 85% of Ugandans living in rural areas

14. RECOMMENDATIONS In order to make “free care” policies in the public effective, MoH should: Increase funding mechanisms for medicines e.g. thru NHIS Improve Procurement and Supply Management (PSM) capacities Increase transparency and accountability in PSM Explore the complementarities envisaged in the Public-Private Partnerships for Health Policy Implement pricing mechanisms for medicines in the private sector to increase affordability